Kristof Chwalisz

Kristof Chwalisz, MD, PhD has held various leadership positions within research and development at Schering AG, Jenapharm, TAP Pharmaceutical Products Inc., Abbott Laboratories and AbbVie Inc. During this time, he was involved in drug discovery and clinical development of Selective Progesterone Receptor Modulators (SPRMs), new estrogens, GnRH agonists and oral GnRH antagonists leading to FDA approval of new indications for leuprolide acetate, and the first FDA approval of an oral GnRH antagonist, elagolix, for the management of pain associated with endometriosis (Orilissa) and heavy menstrual bleeding associated with uterine fibroids (Oriahnn).

Dr. Chwalisz is an internationally renowned pre-clinical and clinical researcher, who is recognized by many scientific contributions in the field of women’s health with focus on new therapies for endometriosis, uterine fibroids and uterine bleeding disorders. He is a co-author of 134 peer-reviewed publications, 37 review article and book chapters and numerous abstracts and patent applications. He has served on several study sections and special review committees for the NIH and FDA. He holds Adjunct Professor positions in the Department of Gynecological Endocrinology and Reproductive Medicine at the Rhine-Westphalia Technical University, Aachen, Germany and the Department of Obstetrics, Gynecology and Reproductive Biology at the Michigan State University, Grand Rapids, MI, USA. Dr. Chwalisz received the medical degree at the Medical University, Poznan, Poland and residency in Obstetrics and Gynecology at the same institution. He completed a fellowship at the Max-Planck Institute of Experimental Endocrinology, Hannover, Germany.